Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.
Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.
复制标题
埃拉瓦环素对 2011 年从美国退伍军人收集的大肠杆菌临床分离株的活性与共存表型和序列类型 131 基因型相关。
DOI：
10.1128/aac.02403-15
复制
发表时间：
2015
影响因子：
4.9
通讯作者：
Thuras,Paul
中科院分区：
文献类型：
--
作者：
Johnson,JamesR;Porter,StephenB;Johnston,BrianD;Thuras,Paul
埃拉瓦环素是一种新的广谱氟环素类药物，具有很强的革兰氏阴性活性，包括对多重耐药菌株。在24个退伍军人事务部医疗中心(2011年)472株对氟喹诺酮类药物敏感和耐药的临床分离株中，肉汤微量稀释法埃拉瓦环素的MIC呈单峰分布，范围从0.03到1.0μg/ml(MIC50为0.125μg/ml，MIC90为0.25μg/ml)。在氟喹诺酮耐药、庆大霉素耐药、多药耐药和131型序列分离株中，埃拉环素的最低抑菌浓度(∼)高出2倍(P<；0.01)。
Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC50of 0.125 μg/ml, MIC90of 0.25 μg/ml). Eravacycline MICs were ∼2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P< 0.01 for each comparison).